Search Results
Jun 05, 2026, 06:16 ET Actualización sobre fármacos innovadores | Kexing Biopharm inscribe al primer sujeto en el ensayo clínico de fase I en China del fármaco oftálmico innovador GB10
biespecífico que se dirige tanto al factor de crecimiento endotelial vascular (FCEV) como a la angiopoyetina-2 (Ang-2). Con una alta concentración de 140 mg/ml, el GB10 inyectable permite un menor volumen de inyección o una dosis más alta, lo que prolonga el intervalo entre dosis. Se espera que permita un régimen
More news about: Kexing Biopharm
Jun 05, 2026, 06:13 ET Atualização sobre medicamentos inovadores | Kexing Biopharm recruta o primeiro participante para o ensaio clínico de Fase I do medicamento oftalmológico inovador GB10, realizado na China
independente pela Shenzhen Kexing. Ele contém um anticorpo biespecífico que tem como alvo ambas as proteínas VEGF e Ang-2. Com uma alta concentração de 140 mg/mL, a injeção de GB10 permite um volume de injeção menor ou uma dosagem mais elevada, aumentando assim o intervalo entre as doses. O objetivo é alcançar
More news about: Kexing Biopharm
Jun 05, 2026, 06:03 ET Sungrow Expands Residential ESS Portfolio with Next-Gen Solution for Reliable Backup Power
provider, unveiled its next-generation residential energy storage solution, expanding its power range from 5 kW to 12 kW with the introduction of the new MG12RL hybrid inverter.
More news about: Sungrow
Jun 05, 2026, 06:02 ET 13 Top Press Releases from May
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialIn TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric
More news about: PR Newswire
Jun 05, 2026, 06:00 ET Nieuws over innovatieve geneesmiddelen | Kexing Biopharm neemt eerste proefpersoon op in de in China uitgevoerde fase I-klinische studie naar het innovatieve oogheelkundige geneesmiddel GB10
Kexing zelfstandig is ontwikkeld. Het bevat een bispecifiek antilichaam dat zich zowel op VEGF als op Ang-2 richt. Dankzij de hoge concentratie van 140 mg/ml maakt GB10 Injectie een kleiner injectievolume of een hogere dosering mogelijk, waardoor het doseringsinterval kan worden verlengd. Naar verwachting
More news about: Kexing Biopharm
Jun 05, 2026, 05:25 ET Mise à jour de médicament novateur | Kexing Biopharm recrute le premier sujet de l'essai clinique de phase I en Chine du médicament innovant ophtalmique GB10
indépendamment par Shenzhen Kexing. Il s'agit d'un anticorps bispécifique ciblant à la fois le VEGF et l'Ang-2. Avec une concentration élevée de 140 mg/ml, GB10 Injection permet de réduire le volume d'injection ou d'augmenter le dosage, ce qui permet d'allonger l'intervalle entre les prises. Il devrait
More news about: Kexing Biopharm
Jun 04, 2026, 17:33 ET IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt
clearance for U.S. sites following completion of Project Optimus requirementsJanuary 29, 2026: Reiterated trial progress, noting FDA agreement on 30 mg optimal biological doseFebruary 6, 2026: 378 patients enrolled, reaching 50% of the targeted 756-patient enrollmentThe lawsuit
More news about: SueWallSt.com
Jun 04, 2026, 16:39 ET Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
pre-filled syringes (PFS). Both the vial and PFS presentations are approved in both strengths available for Lucentis®, 0.3 mg (0.05 mL of 6 mg/mL), and 0.5 mg (0.05 mL of 10 mg/mL). Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial
More news about: Lupin Pharmaceutical, Inc.
Jun 04, 2026, 14:35 ET 革新的医薬品の最新情報｜Kexing Biopharm、革新的眼科用医薬品GB10の中国での第1相臨床試験で初の被験者を登録
GB10は、Shenzhen Kexingが独自に開発した高濃度の眼科用タンパク質医薬製剤です。GB10には、VEGFとAng-2の両方を標的とする二重特異性抗体が用いられています。GB10注射剤は140mg/mLという高濃度であるため、注射液量を減らすか、投与量を増やすことができ、それによって投与間隔を延長できます。「4か月に1回」の投与スケジュールを実現し、患者の治療アドヒアランスを大幅に向上させることが期待されています。前臨床データは、GB10注射剤が生物学的活性と生体内での有効性の両面で国際競争力を備えていることを示しています。レーザー誘発性脈絡膜新生血管（CNV）サルモ
More news about: Kexing Biopharm
Jun 04, 2026, 14:00 ET Supabase Raises $500M at $10.5B to Accelerate Lead in Agentic Infrastructure
https://supabase.link/mg-partner.About SupabaseSupabase is the open source Postgres development platform and leader in agentic infrastructure.
More news about: Supabase
Jun 04, 2026, 10:45 ET Visionary Advances on Multiple Fronts at Pt. Leamington: Phase 2 Drilling Permits Submitted; Prospecting Permits Filed for ~30,000 Ha Regional Land Package; Field Personnel Mobilized to Site
the Eastern's Au+ICP-34, which involved a 30g fire assay coupled with an AAS finish for Au, whereas the ICP-34 involved a four acid digestion of a 200mg subsample with an ICP-OES finish. Overlimits are analysed with Eastern's atomic absorption method, using a 0.200g to 2.00g sample, digested with three
More news about: Visionary Copper and Gold Mines Inc.
Jun 04, 2026, 10:17 ET Breckenridge announces launch of Tofacitinib Tablets, generic equivalent of Xeljanz® by Pfizer
idiopathic arthritis, who have had an inadequate response or intolerance to one or more TNF blockers.Tofacitinib Tablets are available in 5 mg and 10 mg strengths and provide a flexible dosing option to support individualized treatment approaches across approved indications. Please visit
More news about: Breckenridge Pharmaceutical, Inc.
Jun 04, 2026, 08:39 ET Buzz Bomb Emphasizes Sugar-Free, Easy-Access Energy To Keep Daily Energy Levels High
non-liquid single-serve sachets that deliver a punchy 50 mg of fast-acting caffeine sourced from organic, non-GMO coffee beans. Along with being hyper-convenient (they travel well and just need to be opened and
More news about: Buzz Bomb
Jun 04, 2026, 08:33 ET Buzz Bomb Offers Convenient Energy for Busy Summer Schedules
cleaner, more convenient boost that doesn't come with a crash and keeps everyone smiling all day long. The brand's single-serving stick packs deliver 50 mg of tasty sugar-free, fast-acting, under-the-tongue caffeine sourced from organic, non-GMO coffee beans. It is designed for athletes, fitness enthusiasts,
More news about: Buzz Bomb
Jun 04, 2026, 08:11 ET 創新藥進展 | 科興制藥GB10眼科創新藥國內I期臨床首例受試者入組
近日，科興制藥全資子公司深圳科興藥業有限公司（簡稱：深圳科興）自主研發，用於治療新生血管性年齡相關性黃斑變性（nAMD）的眼科創新藥GB10注射液，完成在中國的I期臨床的首例受試者入組給藥，公司創新藥研發進程持續加速。GB10項目是深圳科興自主研發的抗VEGF/Ang-2雙靶點抗體高濃度眼科專用蛋白藥物制劑。GB10 注射液濃度達到140mg/mL，可減少注射體積或提高給藥量，延長給藥周期，預期實現每4個月給藥一次，以提高患者依從性。臨床前數據顯示，GB10 注射液的生物活性和動物藥效具備國際競爭力，在激光誘導的猴CNV（脈絡膜新生血管, choroidal neovascularization）藥效模型中能夠有效抑制眼底血管新生。新生血管性年齡相關性黃斑變性（nAMD
More news about: 科興制藥
Jun 04, 2026, 07:45 ET Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
to Xyrem. Xywav has 131 mg of sodium at the maximum recommended nightly dose whereas other high sodium oxybates have 1640 mg at the equivalent dose. Xywav is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg/night at the recommended
More news about: Jazz Pharmaceuticals plc
Jun 04, 2026, 06:53 ET Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
formulation independently developed by Shenzhen Kexing. It features a bispecific antibody targeting both VEGF and Ang-2. With a high concentration of 140 mg/mL, GB10 Injection allows for a smaller injection volume or higher dosage, thereby extending the dosing interval. It is expected to achieve a "once per
More news about: Kexing Biopharm
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
States showed that rocbrutinib achieved an ORR of 78.3% at doses of 200–300 mg/day in CLL patients previously treated with BTK inhibitors, with an estimated median progression-free survival (PFS) of 28.1 months in the 100–300 mg/day dose range[3]. In January 2026, the global Phase III head-to-head
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
Dieses Arzneimittel enthält weniger als 1 mmol Natrium (23 mg) pro Dosis, d. h. es ist im Wesentlichen „natriumfrei". Dieses Arzneimittel enthält 0,04 mg Polysorbat 80 in jeder Ampulle mit 1 mg und 0,2 mg in jeder Ampulle mit 10 mg. Polysorbate können allergische Reaktionen hervorrufen.UNERWÜNSCHTE
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
connu : Ce médicament contient moins de 1 mmol de sodium (23 mg) par dose, il peut donc être considéré « sans sodium ». Ce médicament contient 0,04 mg de polysorbate 80 dans chaque flacon de 1 mg et 0,2 mg dans chaque flacon de 10 mg. Les polysorbates peuvent provoquer des réactions allergiques.EFFETS
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
účinkom: Tento liek obsahuje menej ako 1 mmol sodíka (23 mg) v jednej dávke, t.j. v podstate neobsahuje sodík. Tento liek obsahuje 0,04 mg polysorbátu 80 v každej injekčnej liekovke s obsahom 1 mg a 0,2 mg v každej injekčnej liekovke s obsahom 10 mg. Polysorbáty môžu vyvolať alergické reakcie.NEŽIADUCE
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
účinkem: Léčivý přípravek obsahuje méně než 1 mmol sodíku (23 mg) v jedné dávce, což znamená, že je v podstatě „bez sodíku". Léčivý přípravek obsahuje 0,04 mg polysorbátu 80 v každé 1mg lahvičce a 0,2 mg v každé 10mg lahvičce. Polysorbáty mohou vyvolat alergické reakce.NEŽÁDOUCÍ
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
działaniu: Produkt leczniczy zawiera mniej niż 1 mmol sodu (23 mg) w dawce, co oznacza, że uznaje się go za „wolny od sodu". Produkt zawiera 0,04 mg polisorbatu 80 w każdej fiolce 1 mg oraz 0,2 mg w każdej fiolce 10 mg. Polisorbaty mogą powodować reakcje alergiczne.DZIAŁANIA
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
conocido: Este medicamento contiene menos de 1 mmol de sodio (23 mg) por dosis, es decir, prácticamente "libre de sodio". Este medicamento contiene 0,04 mg de polisorbato 80 en cada vial de 1 mg y 0,2 mg en cada vial de 10 mg. Los polisorbatos pueden provocar reacciones alérgicas.REACCIONES
More news about: Amgen
Jun 03, 2026, 09:00 ET Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
used as an adjunct to diet and exercise to lower blood sugar in adults with type 2 diabetes.2 The product is available in 50 mg/500 mg and 50 mg-1,000 mg count bottles. "Expanding access to high-quality, affordable medicines remain central to our mission," said Christine Baeder, President,
More news about: Apotex Corp.